← Analyst Upside
AU · rank #3 · 2026-10-23
DIM
PARIS · EUR · $22.84B (USD)
SignalStrong Buy3.5strength 3.5 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.923 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 3 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $240.29 | +14.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +25.22% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +44.9% |
| 52w high | $225.00 |
| Market cap (USD) | $22.84B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Sartorius Stedim Biotech SA provides mission-critical bioprocessing equipment, filtration solutions, and single-use consumables for biopharmaceutical manufacturing.
Rationale
The analyst upside thesis is supported by 80% positive 30-day revision agreement, ~14.9% consensus price target upside, and confirmed FY 2026 guidance showing 7.8% operational revenue growth.
Material risks
- 1Biopharma customers developing selected bioprocessing capabilities or consumables in-house would impair recurring single-use volume growth.
- 2Commoditization and regional supplier competition in standard single-use bags and tubing could exert downward pressure on gross margins.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed